Page 76 - Read Online

Lue et al. J Cancer Metastasis Treat 2022;8:11 https://dx.doi.org/10.20517/2394-4722.2021.193 Page 19 of 25

Copyright
© The Author(s) 2022.

REFERENCES
1. Rosenwald A, Wright G, Chan WC, et al; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to
predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47. DOI PubMed
2. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large b-cell lymphoma. N Engl J Med
2018;378:1396-407. DOI PubMed PMC
3. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic
mechanisms and outcomes. Nat Med 2018;24:679-90. DOI PubMed PMC
4. Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma
with therapeutic implications. Cancer Cell 2020;37:551-568.e14. DOI PubMed PMC
5. Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like
diffuse large B-cell lymphoma. J Clin Oncol 2019;37:190-201. DOI PubMed PMC
6. Song JY, Perry AM, Herrera AF, et al. Double-hit signature with. TP53 ;136:25-6. DOI PubMed PMC
7. Fang JM, Finn WG, Hussong JW, Goolsby CL, Cubbon AR, Variakojis D. CD10 antigen expression correlates with the
t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol 1999;12(3):295-300. (In eng). PubMed
8. Xu Y, McKenna RW, Molberg KH, Kroft SH. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma.
Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol 2001;116:183-90. DOI PubMed
9. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5-
with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-7. DOI PubMed
10. Uherova P, Ross CW, Schnitzer B, Singleton TP, Finn WG. The clinical significance of CD10 antigen expression in diffuse large B-
cell lymphoma. Am J Clin Pathol 2001;115:582-8. DOI PubMed
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature 2000;403:503-11. DOI PubMed
12. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and
supervised machine learning. Nat Med 2002;8:68-74. DOI PubMed
13. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct
subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6. DOI PubMed PMC
14. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one
characterized by host inflammatory response. Blood 2005;105:1851-61. DOI PubMed
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. DOI PubMed
16. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into
molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502. DOI PubMed PMC
17. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse
large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-7. DOI PubMed PMC
18. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB).
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma
treated with immunochemotherapy. Blood 2011;117:4836-43. DOI PubMed
19. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene
expression in formalin-fixed paraffin-embedded tissue. Blood 2014;123:1214-7. DOI PubMed PMC
20. Yoon N, Ahn S, Yong Yoo H, Jin Kim S, Seog Kim W, Hyeh Ko Y. Cell-of-origin of diffuse large B-cell lymphomas determined by
the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Oncotarget 2017;8:22014-22. DOI PubMed PMC
21. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell
lymphomas. N Engl J Med 2008;359:2313-23. DOI PubMed
22. Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-Cell lymphoma cell of origin determined by digital
gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol 2015;33:2848-56. DOI PubMed PMC
23. Vitolo U, Witzig T, Gascoyne R, et al; on behalf of the ROBUST study investigators. ROBUST: first report of phase III randomized
2
study of lenalidomide/R-CHOP (R -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.
Hematol Oncol 2019;37:36-7. DOI
24. Nowakowski GS, Chiappella A, Witzig TE, et al. ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated
ABC-type diffuse large B-cell lymphoma. Future Oncol 2016;12:1553-63. DOI PubMed PMC
25. Maurer MJ, Link BK, Habermann TM, et al. Time from diagnosis to initiation of treatment of DLBCL and implication for potential
selection bias in clinical trials. blood 2016;128:3034. DOI
26. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell 2017;171:481-494.e15.
DOI PubMed PMC
27. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors